Sale!

HAINS Mycobacterium Tuberculosis First and Second Line Drug Resistance Profile Test Cost

Original price was: 1,560 د.إ.Current price is: 1,400 د.إ.

-10%

The “HAINS Mycobacterium Tuberculosis First and Second Line Drug Resistance Profile Test” is a sophisticated diagnostic assessment offered by DNA Labs UAE, designed to detect resistance to both first and second-line anti-tuberculosis drugs. This test is crucial for tailoring the most effective treatment plans for individuals diagnosed with tuberculosis (TB), a contagious bacterial infection caused by Mycobacterium tuberculosis. By identifying specific genetic mutations associated with drug resistance, healthcare providers can make informed decisions on the most suitable medications, thus improving treatment outcomes and reducing the risk of further resistance development. The test is priced at 1400 AED, reflecting the advanced technology and expertise required to perform this comprehensive analysis. It represents a significant step forward in the fight against TB, particularly in cases where drug resistance poses a major treatment challenge.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

HAINS MYCOBACTERIUM TUBERCULOSIS FIRST and SECOND LINE DRUG RESISTANCE PROFILE Test

Test Cost: AED 1400.0

Symptoms and Diagnosis:

If you suspect you have tuberculosis or have been exposed to someone with tuberculosis, your physician may recommend the HAINS MYCOBACTERIUM TUBERCULOSIS FIRST and SECOND LINE DRUG RESISTANCE PROFILE Test. This test is used to detect drug resistance mutations in Mycobacterium tuberculosis, the bacteria that causes tuberculosis. The test can help determine the drug susceptibility or resistance profile of the M. tuberculosis strain.

Test Name: HAINS MYCOBACTERIUM TUBERCULOSIS FIRST and SECOND LINE DRUG RESISTANCE PROFILE Test

Components:

  • Price: AED 1400.0

Sample Condition:

Submit 3 mL (2 mL min.) of sputum, bronchoalveolar lavages, bronchial aspirates, or cultured growth on appropriate media in a sterile screw capped container. Place the sample in a sealed plastic bag and ship refrigerated. Do not freeze the sample.

Report Delivery:

Sample should be submitted by 11 am on Saturday, and the report will be delivered on Friday.

Method:

PCR (Polymerase Chain Reaction) and Line Probe Assay

Test Type:

Tuberculosis

Doctor:

Physician

Test Department:

Molecular Diagnostics

Pre Test Information:

No special preparation is required for this test.

Test Details:

The HAINS (Hybridization in a Liquid Phase Amplification System) assay is a molecular test used for the detection of drug resistance in Mycobacterium tuberculosis. This test is designed to detect both first-line and second-line drug resistance mutations in the bacteria. It specifically targets the genes associated with resistance to the following drugs:

First-line drugs:

  1. Isoniazid (INH)
  2. Rifampicin (RIF)
  3. Ethambutol (EMB)
  4. Pyrazinamide (PZA)
  5. Streptomycin (SM)

Second-line drugs:

  1. Fluoroquinolones (such as moxifloxacin and levofloxacin)
  2. Aminoglycosides (such as kanamycin and amikacin)
  3. Injectable agents (such as capreomycin and viomycin)
  4. Ethionamide (ETH)
  5. Cycloserine (CS)

The HAINS assay detects specific mutations in the target genes that are associated with drug resistance. By identifying these mutations, the test can determine the drug susceptibility or resistance profile of the M. tuberculosis strain. It is important to note that the HAINS assay is a laboratory test and should be performed by trained personnel in a certified laboratory. The results of the test can guide the selection of appropriate drug regimens for the treatment of tuberculosis, especially in cases of drug-resistant strains.

Test Name HAINS MYCOBACTERIUM TUBERCULOSIS FIRST and SECOND LINE DRUG RESISTANCE PROFILE Test
Components
Price 1400.0 AED
Sample Condition Submit 3 mL (2 mL min.) Sputum\/ bronchoalveolar lavages \/ bronchial aspirates \/ Cultured growth on appropriate media in a sterile screw capped container in a sealed plastic bag. Ship refrigerated. DO NOT FREEZE.
Report Delivery SampleSat by 11 am, Report Fri
Method PCR, Line probe assay
Test type Tuberculosis
Doctor Physician
Test Department: MOLECULAR DIAGNOSTICS
Pre Test Information No special preparation required
Test Details

The HAINS (Hybridization in a Liquid Phase Amplification System) assay is a molecular test used for the detection of drug resistance in Mycobacterium tuberculosis. It is designed to detect both first-line and second-line drug resistance mutations in the bacteria.

The HAINS assay specifically targets the genes associated with resistance to the following drugs:

First-line drugs:

1. Isoniazid (INH)

2. Rifampicin (RIF)

3. Ethambutol (EMB)

4. Pyrazinamide (PZA)

5. Streptomycin (SM)

Second-line drugs:

1. Fluoroquinolones (such as moxifloxacin and levofloxacin)

2. Aminoglycosides (such as kanamycin and amikacin)

3. Injectable agents (such as capreomycin and viomycin)

4. Ethionamide (ETH)

5. Cycloserine (CS)

The HAINS assay detects specific mutations in the target genes that are associated with drug resistance. By identifying these mutations, the test can determine the drug susceptibility or resistance profile of the M. tuberculosis strain.

It is important to note that the HAINS assay is a laboratory test and should be performed by trained personnel in a certified laboratory. The results of the test can guide the selection of appropriate drug regimens for the treatment of tuberculosis, especially in cases of drug-resistant strains.